CLDX vs NTLA
Celldex Therapeutics, Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CLDX | NTLA |
|---|---|---|
| Revenue | $1.5M | $67.7M |
| Net income | $-258.8M | $-412.7M |
| Gross margin | 87.1% | 100.0% |
| Net margin | −16748.0% | −609.9% |
| Return on equity | −40.6% | −53.5% |
| Diluted EPS | −$3.90 | −$3.81 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-213.7M | $-395.9M |
| Equity | $527.2M | $671.4M |
| Net debt / equity | −0.14× | — |
| Current ratio | 10.49× | 5.08× |
| Revenue CAGR 5y | −26.9% | 3.1% |
| Profit CAGR 5y | — | — |
NTLA bills 43.8× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | CLDX | NTLA |
|---|---|---|
| FY2025 | $1.5M | $67.7M |
| FY2024 | $7.0M | $57.9M |
| FY2023 | $6.9M | $36.3M |
| FY2022 | $2.4M | $52.1M |
| FY2021 | $4.7M | $33.1M |
| FY2020 | $7.4M | $58.0M |
| FY2019 | $3.6M | $43.1M |
| FY2018 | $9.5M | $30.4M |
| FY2017 | $12.7M | $26.1M |
| FY2016 | $6.8M | $16.5M |
Net income by year
Bottom line
| Fiscal year | CLDX | NTLA |
|---|---|---|
| FY2025 | $-258.8M | $-412.7M |
| FY2024 | $-157.9M | $-519.0M |
| FY2023 | $-141.4M | $-481.2M |
| FY2022 | $-112.3M | $-474.2M |
| FY2021 | $-70.5M | $-267.9M |
| FY2020 | $-59.8M | $-134.2M |
| FY2019 | $-50.9M | $-474.2M |
| FY2018 | $-151.2M | $-85.3M |
| FY2017 | $-93.0M | $-67.5M |
| FY2016 | $-128.5M | $-31.6M |
Advertisement
AdSense · Rectangle 336×280
More in this industry